NCT04740476 Phase 2 Active not recruiting
An Open-Label Extension Study of STK-001 for Patients With Dravet Syndrome Study sponsor: Stoke Therapeutics, Inc · STOK
Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.
Changes Study details Primary completion 2029-03-31 Estimated
Enrollment · participants 60 Estimated
Source updated 2026-02-04 Last update listed in the registry record
Version history
Changes to this trial Last 12 months
Posted 2026-02-04 · 1 field changed
Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Compare wording
− Before Measure: Safety of multiple doses of STK-001
+ After Measure: Safety of multiple doses of zorevunersen
Check registry source
Posted 2025-10-22 · 2 fields changed
Primary completion date changed
Recruitment status changed
− Before Enrolling by invitation
+ After Active not recruiting
Check registry source
This database covers selected trials and recorded edits. Some past edits may be missing, and saved text about the main study measures (endpoints) may be shortened. Check the original registry record when a detail matters. Read our methodology
Trial